Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.40 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.40 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4303080 | 0.86 | HTR7 (0.36) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| Citric Acid SCHEMBL8657218 | 0.83 | KDM4E (0.70) | KDM4ELMNAALDH1A1MAPK1MEN1 | |
| Citric Acid SCHEMBL4902057 | 0.72 | LMNA (0.50) | KDM4ELMNAALDH1A1MAPK1MEN1 | |
| Cizolirtine SCHEMBL2791717 | 0.70 | LMNA (0.65) | KDM4ELMNAALDH1A1MAPK1MEN1 | |
| Cizolirtine SCHEMBL1649170 | 0.70 | LMNA (0.65) | KDM4ELMNAALDH1A1MAPK1MEN1 | |
| SCHEMBL4909282 | 0.69 | KAT2B (0.34) | CYP1A2CYP2D6CYP2C9CYP2C19 | |
| Citric Acid SCHEMBL8657221 | 0.68 | LMNA (0.48) | KDM4ELMNACYP1A2CYP2D6HIF1A | |
| SCHEMBL4908710 | 0.67 | HTR7 (0.35) | KDM4EMEN1CYP1A2CYP2D6CYP2C9 | |
| Phenyltoloxamine SCHEMBL158443 | 0.66 | KDM4E (1.00) | KDM4ELMNAALDH1A1MAPK1MEN1 | |
| SCHEMBL6892797 | 0.66 | DRD2 (0.58) | KDM4ELMNAALDH1A1SMN1; SMN2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200693-A1 | Derivatives of Aryl (or Heteroaryl) Azolylcarbinols (in Particular Cizolirtin Citrate) for the Treatment of Opioid Addiction | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-08-21 | — | — | US | claimed |
| EP-1786420-A1 | DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS FOR THE TREATMENT OF CENTRAL NEUROPATHIC PAIN | Laboratorios del Dr. Esteve S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| US-20070088024-A1 | Active substance combination comprising a carbinol combined to at least an NSAID | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-04-19 | — | — | US | claimed |
| US-20070082893-A1 | Active substance combination | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-04-12 | — | — | US | claimed |
| EP-1755678-A2 | ACTIVE SUBSTANCE COMBINATION OF A CARBINOL COMPOUND AND AN OPIOID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-02-28 | — | — | EP | claimed |
| EP-1746986-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A CARBINOL COMBINED TO AT LEAST AN NSAID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-31 | — | — | EP | claimed |
| EP-1740174-A1 | DERIVATIVES OF ARYL(OR HETEROARYL) AZOLYLCARBINOLS FOR THE TREATMENT OF ENURESIS | Laboratorios del Dr. Esteve S.A. (ES) | 2007-01-10 | — | — | EP | claimed |
| EP-1695704-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-30 | — | — | EP | claimed |
| EP-1690537-A1 | Derivatives of aryl(or heteroaryl) azolycarbinols for the treatment of fibromyalgia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-16 | — | — | EP | claimed |
| EP-1642577-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of central neuropathic pain | Laboratorios del Dr. Esteve S.A. (ES) | 2006-04-05 | — | — | EP | claimed |
| WO-2005097192-A2 | ACTIVE SUBSTANCE COMBINATION OF A CARBINOL COMPOUND AND AN OPIOID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-20 | — | — | WO | claimed |
| EP-1584335-A2 | Active substance combination comprising a carbinol composition and an opioid | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-12 | — | — | EP | claimed |
| US-20050222136-A1 | Active substance combination | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-10-06 | — | — | US | claimed |
| WO-2005067925-A1 | DERIVATIVES OF ARYL(OR HETEROARYL) AZOLYLCARBINOLS FOR THE TREATMENT OF ENURESIS | LABORATORIOS DR. ESTEVE S.A. (ES) | 2005-07-28 | — | — | WO | claimed |
| US-20040142929-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-07-22 | — | — | US | claimed |
| EP-1103243-B1 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES FOR THE TREATMENT OF TROUBLES MEDIATED BY AN EXCESS OF SUBSTANCE P | ESTEVE LABOR DR (ES) | 2004-01-07 | — | — | EP | claimed |
| EP-1086682-B1 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF NEUROGENIC INFLAMMATION | ESTEVE LABOR DR (ES) | 2003-04-16 | — | — | EP | claimed |
| US-6518295-B1 | Such as anxiety, depression, schizophrenia, manic depressive psychosis, sexual dysfunction, drug addiction, cognitive disorders, and locomotive disorders | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2003-02-11 | — | — | US | claimed |
| EP-1103243-A2 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF TROUBLES MEDIATED BY AN EXCESS OF SUBSTANCE P | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-05-30 | — | — | EP | claimed |
| EP-1086682-A2 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF NEUROGENIC INFLAMMATION | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-03-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142929-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence | AADAC, AHR, ABAT | MEN1 4551/4885ESR1 817/4885ESR2 620/4885 |
| US-20070088024-A1 | Active substance combination comprising a carbinol combined to at least an NSAID | PTGS1, PTGS2, PTGES2 | MEN1 2562/4885ESR1 3559/4885ESR2 3112/4885 |
| US-20080200693-A1 | Derivatives of Aryl (or Heteroaryl) Azolylcarbinols (in Particular Cizolirtin Citrate) for the Treatment of Opioid Addiction | CNR2, CNR1, HCRTR2 | MEN1 4392/4885ESR1 1618/4885ESR2 1305/4885 |
| US-20050222136-A1 | Active substance combination | PTGS1, MMP8, TACR1 | MEN1 2541/4885ESR1 2383/4885ESR2 2144/4885 |
| US-20070082893-A1 | Active substance combination | OPRM1, OPRK1, OPRL1 | MEN1 3302/4885ESR1 2943/4885ESR2 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.